for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

日本たばこ産業株式会社

2914.T

現在値

2,818.50JPY

変化

0.50(+0.02%)

出来高

4,835,200

本日のレンジ

2,808.50

 - 

2,824.50

52週レンジ

2,000.00

 - 

2,848.00

∙ 約20分前の相場を表示しています。

適時開示

Japan Tobacco - To Promote Senior Vice President Kei Nakano As Executive Vice President Effective Jan. 1

Nov 25 (Reuters) - Japan Tobacco Inc <2914.T>::* TO PROMOTE SENIOR VICE PRESIDENT KEI NAKANO AS EXECUTIVE VICE PRESIDENT EFFECTIVE JAN. 1.Further company coverage: [2914.t]. (Tokyo Newsroom).

Altria Announces Strategic Partnership With Jt Group And Expanded Heated Tobacco Portfolio

Oct 27 (Reuters) - Altria Group Inc <MO.N>::ALTRIA ANNOUNCES STRATEGIC PARTNERSHIP WITH JT GROUP AND EXPANDED HEATED TOBACCO PORTFOLIO.ALTRIA GROUP INC - CO AND JT GROUP ANNOUNCE JOINT VENTURE FOR U.S. MARKETING AND COMMERCIALIZATION OF HEATED TOBACCO STICK PRODUCTS.ALTRIA GROUP INC - PM USA ENTERED INTO JV WITH SUBSIDIARY OF JT, JAPAN TOBACCO INTERNATIONAL FOR U.S. MARKETING AND COMMERCIALIZATION OF HTS PRODUCTS.ALTRIA GROUP - JV IS STRUCTURED TO EXIST IN PERPETUITY AND ESTABLISHES HORIZON INNOVATIONS LLC.ALTRIA GROUP INC - PM USA HOLDS A 75% ECONOMIC INTEREST IN HORIZON, WITH JTI HAVING A 25% ECONOMIC INTEREST.ALTRIA GROUP - PARTIES EXPECT TO COMBINE SCIENTIFIC AND REGULATORY EXPERTISE TO JOINTLY PREPARE FDA FILINGS FOR LATEST VERSION OF PLOOM HTS PRODUCTS.ALTRIA GROUP INC - PARTIES CURRENTLY EXPECT TO SUBMIT PRE-MARKET TOBACCO PRODUCT APPLICATIONS (PMTA) FOR THESE PRODUCTS IN FIRST HALF OF 2025.ALTRIA GROUP INC - UPON PMTA AUTHORIZATIONS, HORIZON WILL BECOME EXCLUSIVE ENTITY THROUGH WHICH PARTIES MARKET AND COMMERCIALIZE HTS PRODUCTS IN U.S..ALTRIA GROUP INC - JTI WILL SUPPLY PLOOM HTS DEVICES AND PM USA WILL MANUFACTURE MARLBORO HTS CONSUMABLES FOR U.S. COMMERCIALIZATION.

FDA Denies Marketing Of Logic’S Menthol E-Cigarette Products Following Determination They Do Not Meet Public Health Standard

Oct 26 (Reuters) - FDA ::FDA DENIES MARKETING OF LOGIC’S MENTHOL E-CIGARETTE PRODUCTS FOLLOWING DETERMINATION THEY DO NOT MEET PUBLIC HEALTH STANDARD.FDA - ISSUED MARKETING DENIAL ORDERS (MDOS) FOR SEVERAL E-CIGARETTE PRODUCTS CURRENTLY MARKETED BY LOGIC TECHNOLOGY DEVELOPMENT LLC (LOGIC). ((Reuters.Briefs@thomsonreuters.com;)).

Japan Tobacco Inc - JT International Financial Services B.V. To Issue $500 Million In 10-Year Bonds

Oct 20 (Reuters) - Japan Tobacco Inc <2914.T>::JT INTERNATIONAL FINANCIAL SERVICES B.V. TO ISSUE $500 MILLION IN 10-YEAR BONDS.

Japan Tobacco Applied To Japan Ministry Of Finance To Raise Tobacco Retail Prices

Aug 25 (Reuters) - Japan Tobacco Inc <2914.T>::JAPAN TOBACCO: APPLIED TO JAPAN MINISTRY OF FINANCE TO RAISE TOBACCO RETAIL PRICES.Further company coverage: 2914.T. (Reporting by Sakura Murakami). ((Sakura.Murakami@thomsonreuters.com;)).

Japan Tobaccco Group Announces New Operating Model As Company Aims To Strengthen Its Tobacco Business

Feb 9 (Reuters) - Japan Tobacco Inc <2914.T>::GROUP ANNOUNCES NEW OPERATING MODEL AS COMPANY AIMS TO STRENGTHEN ITS TOBACCO BUSINESS.TO CONSOLIDATE CURRENT INTERNATIONAL AND JAPANESE-DOMESTIC TOBACCO BUSINESSES INTO ONE TOBACCO BUSINESS.TO OFFER VOLUNTARY RETIREMENT PROGRAMME AND SEEK RETIREMENT OF ABOUT 1,000 EMPLOYEES.

Japan Tobacco To Sell Tokyo Tower Building To Sumitomo Realty - Nikkei, Citing Sources

Oct 15 (Reuters) - Nikkei::JAPAN TOBACCO INC TO SELL ITS 35-STORY TOKYO TOWER BUILDING TO SUMITOMO REALTY & DEVELOPMENT - NIKKEI, CITING SOURCES.

Japan Tobacco Inc - Transfer Date Of Marketing Approvals Of 6 Anti-Hiv Drugs To Gilead Sciences Kk Set For Dec. 1

Japan Tobacco Inc <2914.T>::JAPAN TOBACCO INC - TRANSFER DATE OF MARKETING APPROVALS OF 6 ANTI-HIV DRUGS TO GILEAD SCIENCES KK SET FOR DEC. 1.

Japan Tobacco Top-Line Results Of Phase 3 Clinical Studies Of JTZ-951 In Anemic Patients With Chronic Kidney Disease In Japan

July 12 (Reuters) - Japan Tobacco Inc <2914.T>::TOP-LINE RESULTS OF PHASE 3 CLINICAL STUDIES OF JTZ-951 IN ANEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE IN JAPAN.RESULTS SHOW BOTH STUDIES MET PRIMARY ENDPOINTS.JT AND TORII <<<4551.T>>> WILL AIM TO SUBMIT MARKETING APPLICATION FOR JTZ-951 IN JAPAN BASED ON RESULTS OF THIS AND OTHER CLINICAL STUDIES.

Japan Tobacco - Top-Line Results Of Phase 3 Clinical Study Of Riona In Adult Patients With Iron Deficiency Anemia In Japan

July 9 (Reuters) - Japan Tobacco Inc <2914.T>::TOP-LINE RESULTS OF PHASE 3 CLINICAL STUDY OF RIONA IN ADULT PATIENTS WITH IRON DEFICIENCY ANEMIA IN JAPAN.RESULTS SHOW STUDY MET PRIMARY ENDPOINT.JT AND TORII PHARMACEUTICAL WILL AIM TO FILE FOR ADDITIONAL INDICATION OF IMPROVING IDA FOR RIONA IN JAPAN BASED ON THIS AND OTHER CLINICAL STUDIES.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up